Personalized drug testing for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of brain tumor called glioblastoma, which is IDH wildtype (a specific genetic type).
- Your tumor does not have a certain DNA marker called MGMT promoter methylation.
- You are scheduled to receive standard radiation and chemotherapy with a drug called temozolomide.
- You have enough tumor tissue available for lab testing.
- You have not had other cancer in the last 5 years (except for some minor skin or early-stage uterine cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
This trial tests a personalized vaccine (made from your own cells) combined with a common chemotherapy drug, temozolomide, for people with newly diagnosed glioblastoma. The goal is to train your immune system to fight the tumor and hopefully slow its growth.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.